UroGen Pharma Ltd. (URGN)

Market Cap	483.18M
Revenue (ttm)	89.36M
Net Income (ttm)	-115.38M
Shares Out	42.20M
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330,421
Open	11.13
Previous Close	11.16
Day's Range	10.86 - 11.48
52-Week Range	10.60 - 20.70
Beta	1.13
Analysts	Strong Buy
Price Target	44.50 (+288.65%)
Earnings Date	Nov 6, 2024

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 201
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $44.5, which is an increase of 288.65% from the latest price.

Price Target

$44.5

(288.65% upside)

Analyst Consensus: Strong Buy